SCHEMBL3528586

SCHEMBL3528586

Cc1ccc(S(N)(=O)=O)c(C)c1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.54
GLO1 Q04760 2/20 0.43
GAA P10253 1/20 0.42
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CA12 O43570 7/20 0.41
CA1 P00915 7/20 0.41
CA2 P00918 7/20 0.41
CA9 Q16790 7/20 0.41
CA3 P07451 3/20 0.41
CA6 P23280 3/20 0.41
CA5A P35218 3/20 0.41
CA7 P43166 3/20 0.41
CA14 Q9ULX7 3/20 0.41
CA5B Q9Y2D0 3/20 0.41
CA4 P22748 2/20 0.41
CA13 Q8N1Q1 2/20 0.41
CISD1 Q9NZ45 1/20 0.40
CYP2C9 P11712 1/20 0.39
MCL1 Q07820 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13687161 0.85 ALDH1A1 (0.58) ALDH1A1GLO1GAALMNAL3MBTL1
SCHEMBL31453879 0.83 ALDH1A1 (0.41) ALDH1A1GLO1LMNAL3MBTL1METAP2
SCHEMBL13687090 0.82 ALDH1A1 (0.51) ALDH1A1GLO1GAALMNAL3MBTL1
SCHEMBL3530146 0.81 METAP2 (0.37) ALDH1A1L3MBTL1CYP2C9MCL1HSD17B10
SCHEMBL13687248 0.77 ALDH1A1 (0.50) ALDH1A1GLO1GAALMNAL3MBTL1
SCHEMBL701462 0.76 ALDH1A1 (0.55) ALDH1A1GAALMNAL3MBTL1CA12
SCHEMBL31643852 0.75 METAP2 (0.45) ALDH1A1LMNAL3MBTL1CA12CA1
SCHEMBL1257806 0.75 METAP2 (0.45) ALDH1A1LMNAL3MBTL1CA12CA1
SCHEMBL11183638 0.75 SMN1; SMN2 (0.48) ALDH1A1GAALMNAL3MBTL1HSD17B10
SCHEMBL23043571 0.75 ALDH1A1 (0.52) ALDH1A1GAALMNAL3MBTL1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105985265-B Indenes -1- subunit sulfonyl benzoyl hydrazine derivatives and its preparation method and application 四川大学 2018-11-13 CN disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 ALDH1A1 2787/4885GLO1 4498/4885GAA 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.